A Review of Ruxolitinib for the Treatment of Myelofibrosis : A Critique of the Evidence

Wade, Rosalind Fay orcid.org/0000-0002-8666-8110, Hodgson, Robert orcid.org/0000-0001-6962-2893, Biswas, Mousumi orcid.org/0000-0001-6781-7400 et al. (2 more authors) (2017) A Review of Ruxolitinib for the Treatment of Myelofibrosis : A Critique of the Evidence. PharmacoEconomics. pp. 203-213. ISSN 1179-2027

Abstract

Metadata

Authors/Creators:
Copyright, Publisher and Additional Information: © 2016 Springer International Publishing. This is an author-produced version of the published paper. Uploaded in accordance with the publisher’s self-archiving policy. Further copying may not be permitted; contact the publisher for details. Embargo period 12 months
Keywords: Ruxolitinib,Myelofibrosis,Splenomegaly
Dates:
  • Accepted: 1 September 2016
  • Published (online): 3 September 2016
  • Published: February 2017
Institution: The University of York
Academic Units: The University of York > Faculty of Social Sciences (York) > Centre for Reviews and Dissemination (York)
Depositing User: Pure (York)
Date Deposited: 15 Sep 2016 11:25
Last Modified: 13 Aug 2019 23:37
Published Version: https://doi.org/10.1007/s40273-016-0447-3
Status: Published
Refereed: Yes
Identification Number: https://doi.org/10.1007/s40273-016-0447-3

Download

Filename: Review_of_Ruxolitinib_for_Myelofibrosis_Revised_final_clean_.docx

Description: Review of Ruxolitinib for Myelofibrosis Revised final (clean)

Share / Export

Statistics